{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-009585","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.217068+00:00","generated_at":"2026-06-27T03:47:17.754738+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Jasper Therapeutics appoints Ronald Martell as CEO effective March 15, 2022","bullets":["Ronald Martell appointed President and CEO, effective March 15, 2022; William Lis transitions to non-executive Chairperson.","Martell receives $675,000 annual salary, 50% bonus target, and option to purchase 4.5% of outstanding shares vesting over 4 years.","Additional 'True-Up Option' for 1.0% of shares granted if Jasper closes equity financing ≥$50 million after start date.","Martell brings 30+ years biotech experience including CEO roles at MorphImmune, Nuvelution, and Achieve Life Sciences.","If terminated without cause or for good reason, Martell receives 18 months base salary subject to release."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-009585","json":"https://secwatch.observer/filing/0001213900-22-009585.json","markdown":"https://secwatch.observer/filing/0001213900-22-009585.md","text":"https://secwatch.observer/filing/0001213900-22-009585.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390022009585/0001213900-22-009585-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390022009585/ea156240-8k_jasperther.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:47:17.754738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4a780f0b5","claim":"Ronald Martell was appointed as President and Chief Executive Officer at Jasper Therapeutics, Inc..","evidence_excerpt":"appointed Ronald Martell, age 60, as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective upon commencement of his employment with the Company, which is expected to be March 15, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390022009585/0001213900-22-009585-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"cdd739a783","claim":"William Lis changed role as non-executive Chairperson at Jasper Therapeutics, Inc..","evidence_excerpt":"William Lis, who is serving as President, Chief Executive Officer and Executive Chairman of the Board, will become the non-executive Chairperson of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390022009585/0001213900-22-009585-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will become"},{"label":"Role","value":"non-executive Chairperson"}],"fact_type":"executive_change"},{"claim_id":"eb590ed30a","claim":"Ronald Martell was appointed as Class III director at Jasper Therapeutics, Inc..","evidence_excerpt":"appointed Ronald Martell, age 60, as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective upon commencement of his employment with the Company, which is expected to be March 15, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390022009585/0001213900-22-009585-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}